NCT05763004 - A Clinical Study to Evaluate the Safety, Tolerability and Efficacy of IOS-1002 Administered Alone and in Combination with Pembrolizumab, a PD-1 Monoclonal Antibody in Advanced Solid Tumors | Biotech Hunter

Enrollment

140

Participants

Timeline

Start Date

March 15, 2023

Primary Completion Date

May 31, 2025

Study Completion Date

May 31, 2025

Conditions

Solid Tumor, Adult

Interventions

DRUG

IOS-1002

monotherapy

DRUG

IOS-1002 + KEYTRUDA® (pembrolizumab)

combination therapy

Trial Locations (5)

NOT_YET_RECRUITING

Monash Health Medical Center, Clayton

NOT_YET_RECRUITING

Austin Health / Cancer Clinical Trials Center, Heidelberg

NOT_YET_RECRUITING

Alfread Health, Melbourne

NOT_YET_RECRUITING

Peter MacCallum Cancer Center, Melbourne

RECRUITING

Linear Clinical Research, Perth